US Stock Insider Trading | Travere Therapeutics disclosed three insider transactions on February 19

2026-02-23 02:14:20

On February 19, 2026, Travere Therapeutics (TVTX) disclosed three insider transactions. Executive REED ELIZABETH E purchased 10,000 shares on February 17, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Executive	REED ELIZABETH E	February 17, 2026	Sell	5,679	27.50	156,200
February 19, 2026	Executive	REED ELIZABETH E	February 17, 2026	Buy	10,000	19.08	190,800
February 19, 2026	Executive	REED ELIZABETH E	February 17, 2026	Sell	4,321	28.26	122,100
February 5, 2026	Executive	Inrig Jula	February 4, 2026	Sell	232	32.85	7,621.20
February 5, 2026	Executive	REED ELIZABETH E	February 4, 2026	Sell	509	32.74	16,700
February 5, 2026	Executive	Cline Christopher R.	February 4, 2026	Sell	1,635	32.14	52,500
February 5, 2026	Executive	REED ELIZABETH E	February 4, 2026	Sell	2,485	32.07	79,700
February 5, 2026	Executive	Cline Christopher R.	February 4, 2026	Sell	110	32.90	3,620
February 5, 2026	Executive	Inrig Jula	February 4, 2026	Sell	1,547	32.11	49,700
February 3, 2026	Executive	ROTE WILLIAM E.	February 3, 2026	Sell	12,000	32.87	409,100

【Company Information】

Travere Therapeutics, Inc. was merged into Desert Gateway Inc. on February 8, 2008, and is registered in Oklahoma.

Retrophin is a development-stage biopharmaceutical company dedicated to developing, acquiring, and commercializing therapies for serious, catastrophic, and rare diseases. Retrophin is actively developing SyntocinonTM Nasal Spray in the U.S. to aid postpartum milk secretion, which can also be used to treat schizophrenia and autism. Currently, Syntocinon Nasal Spray is marketed in Europe and other countries by Novartis and Sigma-Tau to assist postpartum milk production. Additionally, Retrophin is developing RE-034, a synthetic hormone analog composed of 24 amino acids out of the 39 amino acids in ACTH, for the treatment of infantile spasms and nephrotic syndrome. The company is also working on RE-024, a new small molecule potential treatment for pantothenate neurodegenerative diseases. Furthermore, they are developing sparsentan, formerly known as RE-021, a dual-action angiotensin receptor and endothelin receptor antagonist for the treatment of focal segmental glomerulosclerosis. Retrophin has several other clinical programs, including RE-001 for Duchenne muscular dystrophy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes